Edmonton's University of Alberta Hospital — home to one of Canada's major bone marrow transplant and haematology programmes — manages severe aplastic anaemia patients requiring combination immunosuppressive therapy with Eltrombopag. Rompag 50mg provides Edmonton's haematology pharmacy with reliable, affordable high-dose Eltrombopag supply at significantly reduced cost versus brand Revolade.
Alberta's large Indigenous population experiences higher rates of certain blood disorders, and Edmonton's Cross Cancer Institute provides haematology services to patients from across Northern Alberta. Affordable Eltrombopag access supports equitable treatment access for this geographically distributed patient population.
Visit medshopy.com or WhatsApp +91 82650 41513.
Alberta's large Indigenous population experiences higher rates of certain blood disorders, and Edmonton's Cross Cancer Institute provides haematology services to patients from across Northern Alberta. Affordable Eltrombopag access supports equitable treatment access for this geographically distributed patient population.
Visit medshopy.com or WhatsApp +91 82650 41513.
Can aplastic anaemia return after successful treatment with Eltrombopag combination therapy?Yes — relapse is a recognised possibility after achieving haematologic response with immunosuppressive therapy for aplastic anaemia, occurring in approximately 30-35% of patients who initially respond. Relapses can occur months to years after completing treatment, which is why long-term monitoring with regular blood counts continues even after stopping active therapy. Most patients who relapse can be successfully retreated, either with a second course of immunosuppressive therapy or by considering allogeneic stem cell transplant if a suitable donor is available and the patient's clinical condition allows it. Some patients who achieve very deep responses may be able to gradually taper and eventually stop Eltrombopag without relapsing, particularly if their underlying immune dysregulation is well-controlled.